These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 31222044)

  • 21. Using iron-based phosphate binders in phosphate reduction and anemia improvement in patients receiving dialysis: a meta-analysis of randomized controlled trials.
    Zhu Y; Rao J; Liao X; Ou J; Li W; Xue C
    Int Urol Nephrol; 2021 Sep; 53(9):1899-1909. PubMed ID: 33675476
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD.
    Block GA; Block MS; Smits G; Mehta R; Isakova T; Wolf M; Chertow GM
    J Am Soc Nephrol; 2019 Aug; 30(8):1495-1504. PubMed ID: 31278194
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial.
    Dwyer JP; Sika M; Schulman G; Chang IJ; Anger M; Smith M; Kaplan M; Zeig S; Koury MJ; Blumenthal SS; Lewis JB;
    Am J Kidney Dis; 2013 May; 61(5):759-66. PubMed ID: 23369827
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential Impacts of Intravenous Iron Administration and Iron-Containing Phosphate Binders on Serum Intact Fibroblast Growth Factor 23 Levels.
    Honda H; Tanaka K; Michihata T; Shibagaki K; Yuza T; Hirao K; Tomosugi N; Shibata T
    Blood Purif; 2019; 47 Suppl 2():63-69. PubMed ID: 30943476
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study.
    Prats M; Font R; García C; Cabré C; Jariod M; Vea AM
    BMC Nephrol; 2013 Jul; 14():167. PubMed ID: 23902731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status.
    Toblli JE; Di Gennaro F
    PLoS One; 2015; 10(4):e0125528. PubMed ID: 25928811
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of Ferric Citrate in Hyperphosphatemia and Iron Deficiency Anemia in Non Dialysis CKD Patients.
    Nand N; Giri K; Jain D
    J Assoc Physicians India; 2019 Apr; 67(4):53-56. PubMed ID: 31311220
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of ferric citrate hydrate on FGF23 and PTH levels in patients with non-dialysis-dependent chronic kidney disease with normophosphatemia and iron deficiency.
    Iguchi A; Yamamoto S; Yamazaki M; Tasaki K; Suzuki Y; Kazama JJ; Narita I
    Clin Exp Nephrol; 2018 Aug; 22(4):789-796. PubMed ID: 29181658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease.
    Francis C; Courbon G; Gerber C; Neuburg S; Wang X; Dussold C; Capella M; Qi L; Isakova T; Mehta R; Martin A; Wolf M; David V
    Kidney Int; 2019 Dec; 96(6):1346-1358. PubMed ID: 31668632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ferric citrate in the management of hyperphosphataemia and iron deficiency anaemia: A meta-analysis in patients with chronic kidney disease.
    Choi YJ; Noh Y; Shin S
    Br J Clin Pharmacol; 2021 Feb; 87(2):414-426. PubMed ID: 32470149
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and effectiveness of ferric citrate hydrate in serum phosphorus management of patients with chronic kidney disease: a long-term, real-world, observational, post-marketing surveillance study.
    Yokoyama K; Hashimoto T; Okuda Y; Matsumoto Y; Ito K; Yamada R; Susai H; Nishino N
    Clin Exp Nephrol; 2022 Jul; 26(7):688-699. PubMed ID: 35258721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ferric citrate for the treatment of hyperphosphatemia and anemia in patients with chronic kidney disease: a meta-analysis of randomized clinical trials.
    Li L; Zheng X; Deng J; Zhou J; Ou J; Hong T
    Ren Fail; 2022 Dec; 44(1):1112-1122. PubMed ID: 35912897
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ferric citrate controls phosphorus and delivers iron in patients on dialysis.
    Lewis JB; Sika M; Koury MJ; Chuang P; Schulman G; Smith MT; Whittier FC; Linfert DR; Galphin CM; Athreya BP; Nossuli AK; Chang IJ; Blumenthal SS; Manley J; Zeig S; Kant KS; Olivero JJ; Greene T; Dwyer JP;
    J Am Soc Nephrol; 2015 Feb; 26(2):493-503. PubMed ID: 25060056
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepcidin-25/erythroferrone ratio predicts improvement of anaemia in haemodialysis patients treated with ferric citrate hydrate.
    Hara M; Nakamura Y; Suzuki H; Asao R; Nakamura M; Nishida K; Kenmotsu S; Inagaki M; Tsuji M; Kiuchi Y; Ohsawa I; Goto Y; Gotoh H
    Nephrology (Carlton); 2019 Aug; 24(8):819-826. PubMed ID: 30239062
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients?
    Locatelli F; Del Vecchio L
    J Nephrol; 2017 Dec; 30(6):755-765. PubMed ID: 28717990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rationale, design, and characteristics of a trial to evaluate the new phosphate iron-based binder sucroferric oxyhydroxide in dialysis patients with the goal of advancing the practice of E.B.M. (EPISODE).
    Isaka Y; Fujii H; Tsujimoto Y; Teramukai S; Hamano T
    Clin Exp Nephrol; 2018 Aug; 22(4):967-972. PubMed ID: 29536389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ferric Citrate in Patients With Chronic Kidney Disease.
    Block GA
    Semin Nephrol; 2016 Mar; 36(2):130-5. PubMed ID: 27236135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of SBR759, a novel calcium-free, iron (III)-based phosphate binder, versus placebo in chronic kidney disease stage V Japanese patients on maintenance renal replacement therapy.
    Fukagawa M; Kasuga H; Joseph D; Sawata H; Junge G; Moore A; Akiba T
    Clin Exp Nephrol; 2014 Feb; 18(1):135-43. PubMed ID: 23670305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanism of Action and Clinical Attributes of Auryxia
    Ganz T; Bino A; Salusky IB
    Drugs; 2019 Jun; 79(9):957-968. PubMed ID: 31134521
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effects of dose of erythropoiesis stimulating agents on cardiovascular outcomes, quality of life and costs of haemodialysis. the clinical evaluation of the DOSe of erythropoietins (C.E. DOSE) Trial].
    Saglimbene V; D'Alonzo D; Ruospo M; Vecchio M; Natale P; Gargano L; Nicolucci A; Pellegrini F; Craig JC; Triolo G; Procaccini DA; Santoro A; Di Giulio S; La Rosa S; Murgo A; Di Toro Mammarella R; Sambati M; D'Ambrosio N; Greco V; Giannoccaro G; Flammini A; Boccia E; Montalto G; Pagano S; Amarù S; Fici M; Lumaga GB; Mancini E; Veronesi M; Patregnani L; Querques M; Schiavone P; Chimienti S; Palumbo R; Di Franco D; Della Volpe M; Gori E; Salomone M; Iacono A; Moscoloni M; Treglia A; Casu D; Piras AM; Di Silva A; Mandreoli M; Lopez A; Quarello F; Catizone L; Russo G; Forcellini S; Maccarone M; Catucci G; Di Paolo B; Stingone A; D'Angelo B; Guastoni C; Pasquali S; Minoretti C; Bellasi A; Boscutti G; Martone M; David S; Schito F; Urban L; Di Iorio B; Caruso F; Mazzoni A; Musacchio R; Andreoli D; Cossu M; Li Cavoli G; Cornacchiari M; Granata A; Clementi A; Giordano R; Guastoni C; Barzaghi W; Valentini M; Hegbrant J; Tognoni G; Strippoli GF
    G Ital Nefrol; 2013; 30(2):. PubMed ID: 23832463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.